Kornimate/medical-research-clean huggingface dataset:
tai chi for patients with essential hypertension

Conditions: Hypertension

Summary: several studies investigating tai chi for hypertension have been carried out. however, investigators found the results were in high heterogeneity and poor methodological quality. thus, investigators intend to provide high quality of the effectiveness and safety of tai chi for essential hypertension.


Eligibility criteria:
inclusion criteria: 1. participants aged between 45 to 80 years; 2. participants diagnosed with mild to moderate hypertension, and meet the diagnostic criteria of mild to moderate hypertension according to 2018 chinese guidelines for the management of hypertension (140≤sbp≤169 and/or 90≤dbp≤109); 3. participants with or without antihypertensive medication; 4. participants with no regular exercise in the past 3 months; 5. participants willing to comply with the study protocol; 6. participants willing to sign informed consent form. exclusion criteria: 1. participants diagnosed with secondary hypertension or refractory hypertension; 2. participants with severe medical visceral condition and chronic diseases, such as diabetes, epilepsy, severe depression or anxiety, psychosis; 3. participants with severe bone and joint diseases or motor dysfunction limit ability to participant exercise; 4. participants with severe cognitive decline (mini-mental state examination score, ≤ 20) 5. participants with weak muscle, poor balance or limited vision that would impede full participation in the study; 6. patients participate in other clinical trials at the same time.

Keywords: tai chi hypertension randomized controlled trial
medical trial: appraising medical trial experiences of rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: historically, participation in clinical trials has been highly skewed towards specific demographic groups. however, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. this study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. this data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future rheumatoid arthritis patients.


Eligibility criteria:
inclusion criteria: * patient has been diagnosed with rheumatoid arthritis * patient has self-identified as planning to enroll in an interventional clinical trial * patient is 18 years old exclusion criteria: * ecog score of 4 * patient is pregnant * inability to perform regular electronic reporting * patient does not understand, sign, and return consent form
breath-holding spells and its management study

Conditions: Breath-holding Spell

Summary: the goal of this prospective population-based study is to evaluate the new disease description and management guidelines for breath-holding spells in children (hellström schmidt et al, acta paediatrica 2024) below the age of 5 years in southern sweden. the main questions it aims to answer are: * does the disease description and management guidelines lead to the expected reduction in diagnostic interventions and are the clinical managements guidelines safe to use? * if iron supplementation is given, does it reduce the frequency and severity of the spells? * what information and support does parents to children with breath-holding spells need? participants will undergo evaluation by a medical doctor and if typical breath-holding spells are diagnosed, be managed according to the new guidelines. if iron deficiency is found, iron supplementation is recommended. digital surveys will be distributed and parents of patients with frequent spells will be eligible for participation in an interview sub-study.

please see the study plan among the documents.

Eligibility criteria:
inclusion criteria: * below 5 years of age * resident in region skåne (sweden) * suspected breath-holding spell exclusion criteria: * previous investigation for breath-holding spell (previous spells are not a reason for exclusion)

Keywords: disease definition electrocardiography iron deficiency anemia long qt syndrome parental support
a study on the treatment of parkinson's disease with autologous neural stem cells

Conditions: Parkinson Disease

Summary: this is a single center, single arm and open-label study to investigate the safety and efficacy of ips-ncs with parkinson's disease


Eligibility criteria:
inclusion criteria: 1. the subject is able to understand the research requirements, provide written informed consent, and complete the study in accordance with the procedures; 2. the subject is clearly diagnosed with parkinson's; 3. recorded disease progression over the past 6 months; 4. vital organ function is satisfied: cardiac ultrasound indicates cardiac ejection fraction ≥ 50%, no obvious abnormality in ecg; blood oxygen saturation ≥ 90%; creatinine clearance calculated by cockcroft-gault formula ≥ 40ml/min; alt and ast ≤ 3 times the normal range, total bilirubin ≤ 2.0 mg/dl; 5. blood routine: hgb≥80g/l, anc≥1×109/l, plt≥50×10/l; exclusion criteria: 1. mental illness or a neurological disease not associated with parkinson's disease; 2. serious other concomitant diseases (tumor, organ failure, etc.); 3. subjects used a large amount of corticosteroids, immunoglobulins, immunosuppressants before entering the study; 4. participated in other clinical trials of cell preparations and participated in other clinical trials within 3 months; 5. there are already cognitive impairments or depressions, etc., and the research cannot be completed well; 6. female subjects who are breast-feeding or have a pregnancy plan recently.
assessing a stool symptom screener in patients with chronic opioid-induced constipation

Conditions: Opioid-induced Constipation

Summary: this qualitative research is to assess the validity of the stool symptom screener that will be used in patients with chronic opioid-induced constipation to determine the adequacy of their response to laxatives.

assessing the content validity of a stool symptom screener in patients with chronic opioid-induced constipation

Eligibility criteria:
inclusion criteria: * receiving a stable maintenance opioid regimen (total daily dose of 30-1000mg of oral morphine, or equianalgesic amounts of 1 or more other opioid therapies) for a minimum of 4 weeks for non-cancer related pain. * development of constipation symptoms since starting opioids. * taken laxatives to help with bowel movements for at least four days over the past 2 weeks. exclusion criteria: * receiving opioid regimen for treatment of pain related to cancer. * participated in any clinical trial or research study relating to opioid use and/or constipation within the past year. * history of cancer within 5 years from the time of screening. * has medical condition(s) and/or treatment(s) associated with diarrhea, intermittent loose stools, or constipation (e.g., fecal incontinence or chronic idiopathic constipation). * has irritable bowel syndrome (ibs) or chronic functional constipation.

Keywords: opioid-induced constipation
opioids, low nicotine cigarettes, and chronic pain

Conditions: Chronic Pain; Tobacco Use; Opioid Substitution Treatment

Summary: the purpose of this study is to evaluate the effects of switching to very low nicotine content (vlnc) cigarettes versus normal nicotine content (nnc) cigarettes on craving, withdrawal, and pain among individuals with chronic pain who smoke cigarettes daily and are attending office-based buprenorphine treatment (obbt).


Eligibility criteria:
inclusion criteria: * aged 21+ years who smoke cigarettes daily * chronic non-cancer musculoskeletal pain secondary to structural changes (e.g., low back pain, osteoarthritis) * have received stable office-based buprenorphine treatment for opioid use disorder for at least 30 days * self-report smoking at least 10 cigarettes/day * expired breath carbon monoxide (co) level \>8 ppm * have a smartphone capable of running software for ecological momentary assessment * open to exploring the possibility of quitting smoking exclusion criteria: * pain specifically due to cancer * other significant health problems * major surgery within the past 6 months or planned surgery within the timeframe of the study * current disability litigation * use of electronic cigarettes or other non-cigarette tobacco products \> 9 of the past 30 days * current use of nicotine replacement therapy or other cessation treatment * current daily or near-daily cannabis use * history of psychotic disorder * acute suicidality or current unstable psychiatric disorder * positive pregnancy test * actively seeking smoking cessation treatment
the effects of double plasma molecular adsorption system in acute on chronic liver failure patients

Conditions: Acute-On-Chronic Liver Failure; Acute on Chronic Hepatic Failure

Summary: acute liver failure patients posed high mortality rate despite receiving standard therapy. the severity and mortality even higher in patients with underlying liver disease. acute liver failure cause hyperinflammatory response in early stage and immunoparalysis in later stage. the surge of proinflammatory cytokines leads to multiorgan failure and more liver injury. subsequent immunoparalysis may lead to lethal secondary infections. liver support system had been used in acute and acute ontop chronic liver disease for last several decades. double plasma molecular adsorption system (dpmas) is one of the promising non-biological liver support system that have been extensively investigated in acute ontop chronic liver failure from hepatits b viral. dpmas circuit consist of bs330 (bilirubin adsorber) and ha330 (cytokines adsorber). thus, dpmas can also remove various cytokines. the effect of dpmas on immune function in these patients has not been explored. recent randomized controlled trial by srisawat et al. demonstrated improvement of mhla-dr in septic shock patients who received polymyxin b extracorporeal therapy compare to control arm. since liver failure show change of immunological profile resemble to sepsis. investigators proposed that removal of toxic liver toxins and lethal cytokines by dpmas will improve immunological profiles in acute ontop chronic liver failure patients. investigators plan to conduct a randomized controlled trial in acute ontop chronic liver failure patients who admitted to intensive care unit. investigators plan to compare the immunomodulatory effects of dpmas with standard treatments.


Eligibility criteria:
inclusion criteria: 1. age 18 or more 2. diagnosis of acute ontop chronic liver failure by asian pacific association for the study of the liver (apasl) criteria 3. admitted to intensive care unit exclusion criteria: 1. pregnancy 2. received steroid treatment 3. expected dead within 24 hour 4. wbc \< 500/mm3 5. allergy to dpmas 6. history of organ transplant 7. terminal illness with do not resuscitation order

Keywords: hemoperfusion acute-on-chronic liver failure cytokine adsorbant therapy ha-330
developing a diabetic foot ulcer protocol

Conditions: Diabetic Foot Ulcers

Summary: the purpose of this study is to determine which treatment, over 6 months, will promote healing of diabetic foot ulcers that are not infected in the most efficient, cost-effective way.

this pilot study will be conducted in harris county hospital district (hchd) community health centers and wound care clinics. the study will use random assignment of patients who meet inclusion criteria to: postoperative shoe with or without collagen; removable air-boot with or without collagen; or monitored air-boot with or without collagen. all treatment is standard of care. enrollment will occur at a clinic appointment. during the consent appointment, follow-up will be scheduled. patients whose wound meets study criteria will be approached by a podiatrist or therapist during a wound care visit. an a1c will be obtained, if not done within the past 3 months. a convenience sample will be drawn from people with diabetes, aged 18 or more, who meet inclusion criteria. frequency of visits will be: * patients with monitored air-boot: weekly * all others: every 2 weeks at each visit there will be a dressing change, wound assessment and review of how many times shoe/boot was removed or not used during the preceding 1 or 2 weeks. should healing not occur within 6 months or the wound progress, the patient will be referred for evaluation of possible vascular involvement.

Eligibility criteria:
inclusion criteria: * adult - over 18 years of age * diabetes with an a1c of less than or equal to 9% - if no a1c result is available within the past 3 months, one will be drawn to qualify the patient for the study * no evidence of circulatory compromise * posterior tibial or pedal pulse present on palpation * no pallor on elevation * no dependent rubor * loss of sensation on forefoot using monofilament * wound or callus on only 1 foot * wound classification - wagner grade 1, non-infected * ulcer present for 1 - 3 months * ulcer of forefoot only * no previous ulcer of that foot or amputation of either extremity * wound size \< 1" diameter * wound bed pink exclusion criteria: * diagnoses with unpredictable trajectory or healing ability, i.e. * psychiatric disorders * cancer * esrd not eligible for dialysis * hiv * previous lower extremity amputation * charcot foot * evidence of circulatory compromise * absence of pulses * decreased capillary refill (\> 3 seconds) * trophic skin changes - shiny, hairless toes * ankle brachial index \< 0.8

Keywords: diabetes foot ulcers off-loading collagen wagner 1
hippotherapy simulators on trunk control and upper extremity functions in cerebral palsy

Conditions: Cerebral Palsy

Summary: the hippotherapy simulator imitates the three-dimensional mechanical movement and walking of the horse and transfers the mechanical effect to the rider during hippotherapy. the aim of this study was to investigate the effect of exercise program with hippotherapy simulator on upper extremity functions and trunk control of individuals with cerebral palsy.all individuals diagnosed with cerebral palsy who agree to participate in the study and meet the inclusion criteria will be randomly divided into two groups as study and control group. in addition to conventional physiotherapy, the study group will be trained in the hippotherapy simulature for 15 minutes a day, 5 days a week for 4 weeks.n addition to conventional physiotherapy, the control group will be allowed to sit in the hippotherapy simulature for 15 minutes a day, 5 days a week for 4 weeks. however, the simulator will be kept in closed position to prevent oscillations.

cerebral palsy can be defined as a non-progressive lesion that occurs in the brain that has not yet completed its development and causes activity limitation with movement and posture problems. although the disorders seen in cerebral palsy are not progressive, these individuals may experience losses in their current motor functions in later ages and this may cause losses in their independence and activities of daily living. the hippotherapy simulator imitates the three-dimensional mechanical movement and walking of the horse and transfers the mechanical effect to the rider during hippotherapy. the aim of this study was to investigate the effect of exercise program with hippotherapy simulator on upper extremity functions and trunk control of individuals with cerebral palsy.all individuals diagnosed with cerebral palsy who agree to participate in the study and meet the inclusion criteria will be randomly divided into two groups as study and control group. in addition to conventional physiotherapy, the study group will be trained in the hippotherapy simulature for 15 minutes a day, 5 days a week for 4 weeks.n addition to conventional physiotherapy, the control group will be allowed to sit in the hippotherapy simulature for 15 minutes a day, 5 days a week for 4 weeks. however, the simulator will be kept in closed position to prevent oscillations.

Eligibility criteria:
inclusion criteria: * being between 6-18 years old * being diagnosed with unilateral spastic type cerebral palsy * voluntariness of the family and individuals to participate in the study * being at i, ii, iii level according to the hand skills classification system * to have the cognitive development to cooperate exclusion criteria: * having undergone any orthopedic and/or neurological surgery and/or bont a operation within the last 6 months * having a history of epilepsy * hearing and/or vision loss at a level that prevents participation in the study

Keywords: cerebral palsy hippotherapy smilator upper extremity
dalpiciclib plus fulvestrant with pyrotinib in hormone receptor-positive, her2-low advanced breast cancer that progressed on previous cdk4/6i plus ai therapy

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if the triplet combination of dalpiciclib, fulvestrant, and pyrotinib is safe and effective in the treatment of hormone receptor-positive, her2-low locally advanced/metastatic breast cancer following treatment with an aromatase inhibitor plus a cdk4/6 inhibitor (palbociclib abemaciclib or ribociclib). the study will employ a bayesian optimal phase ii (bop2) design which explicitly controls the type i error rate, thereby bridging the gap between bayesian designs and frequentist designs, and has favorable operating characteristics with higher power and lower risk of incorrectly terminating the trial than some existing bayesian phase ii designs.


Eligibility criteria:
inclusion criteria: 1. men or women at least 18 years of age with histologically or cytologically confirmed adenocarcinoma of the breast with unresectable or metastatic disease. 2. most recent tumor biopsy or surgical resection specimen must be either estrogen-receptor (er) positive, progesterone receptors (pgr) positive, or both, as defined by immunohistochemistry (ihc) ≥1% (as per the american society of clinical oncology (asco)-college of american pathologists (cap) guidelines). 3. her2-low breast cancer defined as ihc 2+/ish- or ihc 1+ (ish- or untested). (as per the asco-cap guidelines). 4. postmenopausal status or receiving ovarian ablation with a gnrh agonist such as goserelin. postmenopausal status is defined by any one of the following criteria: * prior bilateral oophorectomy. * age ≥60 years. * age \<60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifen, or ovarian suppression) and fsh, lh, and estradiol in the postmenopausal range per local normal if the patient does not meet criteria for postmenopausal status but is receiving ovarian ablation therapy with a gonadotropin-releasing hormone (gnrh) agonist such as goserelin, the patient is eligible for this study, provided that the gnrh agonist is started at least 2 weeks prior to c1d1 of anti-estrogen therapy. 5. patient must have either measurable disease by recist 1.1 or only bone lesions in absence of measurable disease. 6. eastern cooperative group (ecog) performance status of 0 or 1. 7. previously treated on cdk 4/6 inhibitor(palbociclib, abemaciclib or ribociclib) with ai for at least 6 months 8. adequate bone marrow and organ function. exclusion criteria: 1. patient with symptomatic visceral disease or any disease burden. 2. patient has received more than one line of chemotherapy for advanced disease. 3. previous treatment with dalpiciclib /pyrotinib /adce for advanced disease. 4. progressed on more than one cdk 4/6 inhibitor 5. patients with persistent symptoms and unstable brain metastases; 6. any condition that makes the patient ineligible for endocrine therapy per the investigator's best judgment
the efficacy of influenza vaccine program in children with juvenile idiopathic arthritis. a single centre results from hungary

Conditions: Juvenile Idiopathic Arthritis

Summary: the aim of our study is to compare the immune function of patient treated with dmard (methotrexate), or tumor necrosis factor (tnf)-alpha inhibitor (adalimumab) to healthy children. the study consists of three parts. in each part physical examination and routine laboratory tests are done. at the first examination flow cytometry analysis is performed, after that the participants are immunized with influenza (3fluart) vaccine. at part two and three further flow cytometry is carried out and seroconversion is measured.


Eligibility criteria:
inclusion criteria: * jia (oligoarticular, polyarticular) treated with mtx or mtx/adalimumab * healthy controls exclusion criteria: * children with infection * children with active jia disease * jia other than oligoarticular, polyarticular type
f18 ef5 pet/ct imaging in patients with brain metastases from breast cancer

Conditions: Brain Metastases From Breast Cancer

Summary: to estimate the presence of hypoxia in individual lesions after radiotherapy in patients with brain metastases from breast cancer as identified by f18 ef5 pet/ct imaging.


Eligibility criteria:
inclusion criteria: * subjects with measurable brain metastases of at least 1 cm in any plane based on anatomic imaging. * subjects with prior resection of brain metastases with progressions on brain mri. * histologic confirmation of breast cancer. * age of study subject must be \> 18 years. * ecog performance status ≤ 2. * ability to undergo brain mr and pet imaging * study subjects must have normal organ and marrow function as defined below: wbc \>2,000/mmᶟ, platelets \>90,000/mmᶟ, total bilirubin \<2.0 mg/dl, creatinine \<2.0 mg/dl. * the effects of ef5 on the developing human fetus are unknown. for this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation (1 month). should a woman become pregnant pr suspect she is pregnant while participating in this study, she should inform her treating physician immediately. women of childbearing potential will have a urine pregnancy test the day of the f18 -ef5 pet scan prior to the f18 -ef5 injection. * ability to understand, participate and provide a documented signed informed consent. * subjects who are allergic to gadolinium will have mri scans without gadolinium contrast. exclusion criteria: * history of allergic reactions attributed to flagyl (metronidazole), which has a chemical structure similar to ef5. * pregnant women are excluded because ef5 has an unknown risk for adverse events in fetuses and nursing infants secondary the administration of ef5 to the mother. breastfeeding should be discontinued if ef5 is administered to the mother. * subject has any other condition or personal circumstance that, in the judgement of the investigator, might interfere with the collection of complete good quality data. * subjects who are unable to provide informed consent. * patients with prior whole brain radiotherapy. * patients with moderate to severe renal failure, defined as estimated gfr less than 30 ml/lmin 1.73m²